Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01815450 · ClinicalTrials.gov registry record · Phase 2
BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris
A Phase 2 study, sponsored by Braintree Laboratories.
- Completed
- Registry status
- Phase 2
- Development phase
- 369
- Enrollment target
NCT01815450: Completed Phase 2 study, sponsored by Braintree Laboratories.
NCT01815450 is a Phase 2 study that has completed, run by Braintree Laboratories. The registered enrollment target is 369 participants, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (177% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01815450, a Phase 2 study, has completed, sponsored by Braintree Laboratories.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 369 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the safety and efficacy of BLI1100 formulations to placebo for the treatment of moderate to severe acne vulgaris.
Interventions
- DRUG Placebo
- DRUG BLI1100
- DRUG BLI1100 - modified formulation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 369 participants |
| Start Date | 2013-02 |
| Phase | Phase 2 |
What the finished NCT01815450 record still lists
NCT01815450 is an interventional study that assigns participants to a tested intervention. The registered 369 participants enrollment target is mid-sized for trials with a published cap, above the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (177% higher).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT01815450 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01815450 about?
NCT01815450 is a clinical study titled "BLI1100-202: BLI1100 for the Treatment of Moderate to Severe Acne Vulgaris". The purpose of this study is to compare the safety and efficacy of BLI1100 formulations to placebo for the treatment of moderate to severe acne vulgaris.
What is the current status of trial NCT01815450?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 369 participants. The study started on 2013-02.
What interventions are being tested in trial NCT01815450?
The interventions under investigation include: Placebo (DRUG), BLI1100 (DRUG), BLI1100 - modified formulation (DRUG).
Who is sponsoring clinical trial NCT01815450?
This trial is sponsored by Braintree Laboratories, which has 49 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01815450's enrollment target sits among peer trials
369 121st of 2000 higher than 1,880 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06114836 · 369 participants · NA
GERD Infant Feeding Therapeutics Trial (GIFT Trial)
- NCT06585410 · 369 participants · Phase 3
Study of Intralesional Cemiplimab in Adult Patients With Early Stage Cutaneous Squamous Cell Carcinoma
- NCT07256717 · 369 participants · NA
BPIT 5-Week Multi-Site Study: Movement Efficiency, Mobility & Neuromuscular Adaptation
- NCT02332668 · 370 participants · Phase 1
A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia